CRIS Current Research Information System

VERUCCHI, GABRIELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.350
EU - Europa 5.651
AS - Asia 4.871
SA - Sud America 382
AF - Africa 364
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 4
Totale 19.632
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.301
GB - Regno Unito 1.923
SG - Singapore 1.667
CN - Cina 1.336
VN - Vietnam 868
DE - Germania 711
SE - Svezia 707
IT - Italia 686
HK - Hong Kong 397
IN - India 329
RU - Federazione Russa 322
UA - Ucraina 314
BR - Brasile 291
FR - Francia 243
IE - Irlanda 220
ZA - Sudafrica 114
EE - Estonia 107
NL - Olanda 105
CI - Costa d'Avorio 97
TG - Togo 85
FI - Finlandia 77
JP - Giappone 60
BG - Bulgaria 58
AR - Argentina 50
JO - Giordania 44
CH - Svizzera 36
AT - Austria 29
CA - Canada 29
KR - Corea 28
ES - Italia 25
ID - Indonesia 25
SC - Seychelles 25
NG - Nigeria 22
PL - Polonia 17
BE - Belgio 16
GR - Grecia 16
MX - Messico 16
EC - Ecuador 15
BD - Bangladesh 14
IQ - Iraq 12
IR - Iran 11
LB - Libano 10
TR - Turchia 10
UZ - Uzbekistan 10
PK - Pakistan 9
AU - Australia 8
CL - Cile 8
LT - Lituania 7
EG - Egitto 6
IL - Israele 6
LU - Lussemburgo 6
MA - Marocco 6
AZ - Azerbaigian 5
CO - Colombia 5
RO - Romania 5
AE - Emirati Arabi Uniti 4
PE - Perù 4
A2 - ???statistics.table.value.countryCode.A2??? 3
KE - Kenya 3
MY - Malesia 3
PT - Portogallo 3
PY - Paraguay 3
TW - Taiwan 3
VE - Venezuela 3
AL - Albania 2
AM - Armenia 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
DZ - Algeria 2
HR - Croazia 2
KZ - Kazakistan 2
MM - Myanmar 2
NP - Nepal 2
NZ - Nuova Zelanda 2
OM - Oman 2
RS - Serbia 2
SA - Arabia Saudita 2
SN - Senegal 2
UY - Uruguay 2
AO - Angola 1
BH - Bahrain 1
BY - Bielorussia 1
BZ - Belize 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
KG - Kirghizistan 1
KW - Kuwait 1
MD - Moldavia 1
ME - Montenegro 1
MK - Macedonia 1
MN - Mongolia 1
NO - Norvegia 1
PA - Panama 1
PS - Palestinian Territory 1
SI - Slovenia 1
TH - Thailandia 1
TJ - Tagikistan 1
TN - Tunisia 1
Totale 19.629
Salva come PNG Salva come JPEG
Città #
Southend 1.779
Singapore 1.067
Fairfield 975
Ashburn 909
Chandler 660
Houston 484
Woodbridge 473
Seattle 439
Wilmington 428
Hong Kong 396
Santa Clara 336
Cambridge 310
Princeton 309
Ann Arbor 264
Dublin 219
Dong Ket 213
Beijing 196
Jacksonville 195
Boardman 191
Ho Chi Minh City 173
Bologna 156
Hanoi 138
Westminster 130
Nanjing 126
Hefei 125
Padova 118
Los Angeles 102
Dallas 99
Abidjan 97
Berlin 89
Lomé 85
San Diego 80
New York 76
Shenyang 69
Saint Petersburg 63
Buffalo 62
Helsinki 60
Jinan 58
Tokyo 58
Sofia 57
Redmond 48
Florence 46
Amman 44
Milan 44
Changsha 42
Nanchang 42
Dearborn 40
Guangzhou 38
Hebei 36
Des Moines 33
Redondo Beach 33
Mülheim 31
Turin 31
Zhengzhou 31
Frankfurt am Main 29
Medford 29
Seoul 28
Tianjin 28
Chicago 27
London 27
Falls Church 26
Nuremberg 25
Munich 24
São Paulo 24
Norwalk 23
Haiphong 22
Abeokuta 21
Bern 21
Bremen 21
Phoenix 21
Redwood City 21
Falkenstein 19
Jiaxing 19
Mahé 19
Olalla 19
Rome 19
Shanghai 19
Hangzhou 18
Bühl 17
Ningbo 17
Verona 16
Yubileyny 16
Moscow 15
Vienna 15
Atlanta 14
Benevento 14
Brussels 14
Fuzhou 14
Haikou 14
Lanzhou 14
Jakarta 13
Rio de Janeiro 13
Stockholm 13
Wuhan 13
Biên Hòa 12
Da Nang 12
Hải Dương 12
Taiyuan 12
The Dalles 12
Toronto 12
Totale 13.256
Salva come PNG Salva come JPEG
Nome #
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus 451
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy 373
Accuracy of elastography point quantification and steatosis influence on assessing liver fibrosis in patients with chronic hepatitis C 268
Type 1 autoimmune hepatitis: patterns of clinical presentation and differential diagnosis of the 'acute' type. 234
Clinical Impact and Safety of Anticoagulants for Portal Vein Thrombosis in Cirrhosis 223
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 218
A novel stop codon mutation within the hepatitis B surface gene is detected in the liver but not in the peripheral blood mononuclear cells of HIV-infected individuals with occult HBV infection. 210
Assessing the impact of hepatitis C virus coinfection on lopinavir/ritonavir trough concentrations in HIV-infected patients. 204
Extended infusion of β-lactams for bloodstream infection in patients with liver cirrhosis: an observational multicenter study 204
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) 203
Vitamin E for the treatment of E-antigen-positive chronic hepatitis B in paediatric patients: results of a randomized phase 2 controlled study. 202
Ultrastructural liver mitochondrial abnormalities in HIV/HCV-coinfected patients receiving antiretroviral therapy 196
Chagas Disease in a Non-endemic Country: A Multidisciplinary Research, Bologna, Italy 189
Infectious diseases team for the early management of severe sepsis and septic shock in the emergency department 186
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 184
Seroprevalence of five neglected parasitic diseases among immigrants accessing five infectious and tropical diseases units in Italy: a cross-sectional study 181
Cardiovascular risk factors and ultrasound evaluation of carotid atherosclerosis in patients with HIV-1 infection. 181
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 180
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 177
Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management 174
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 172
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 164
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 163
Human immunodeficiency virus and hepatitis C virus coinfection: epidemiology, natural history, therapeutic options and clinical management 162
Liver decompensation predicts ribavirin overexposure in hepatitis C virus patients treated with direct-acting antivirals 162
Cytopenias during treatment of HIV-HCV-coinfection with pegylated interferon and ribavirin: safety analysis of the OPERA study 160
Amiodarone-related pneumonitis and peripheral neuropathy in an elderly patient 160
Prognostic Role of Bacterial and Fungal Infections in Patients with Liver Cirrhosis with and without Acute-on-Chronic Liver Failure: A Prospective 2-Center Study 159
Plasma Levels of VCAM-1, ICAM-1, E-Selectin, and P-Selectin in 99 HIV-positive patients versus 51 HIV-negative healthy controls. 158
Chronic hepatitis with diffuse steatosis and slight fibrosis related to etretinate therapy 157
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 157
The Italian compassionate use of sofosbuvir observational cohort study for the treatment of recurrent hepatitis C: clinical and virological outcomes 156
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 155
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. 154
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 154
Favourable evolution of virological and immunological profiles in treated and untreated patients in Italy in the period 1998-2008 153
Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection. 151
Effect of aging, glucose level, and HIV viral load on response to treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected women. 151
Prevalence And Mutational Pattern Of Occult Hepatitis B Virus Isolated From Liver Tissue Of HIV Infected Patients 150
A New Two-Dimensional Shear Wave Elastography for Noninvasive Assessment of Liver Fibrosis in Healthy Subjects and in Patients with Chronic Liver Disease - Eine neue zweidimensionale Shear-Wave-Elastografie zur nicht-invasiven Beurteilung der Leberfibrose bei Gesunden und bei Patienten mit chronischer Lebererkrankung 149
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 148
Occult HBV infection in PBMCs of HIV+ individuals 147
High prevalence of the metabolic syndrome in HIV-infected patients: impact of different definitions of the metabolic syndrome. 146
COVID-19 in patients with HIV-1 infection: a single-centre experience in northern Italy 146
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: Data from the Icona Foundation cohort 145
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 145
Membranoproliferative glomerulonephritis associated with human immunodeficiency virus, hepatitis B and hepatitis C virus coinfection: case report and literature review. 144
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 144
HIV-1 subtype C transmission network: The phylogenetic reconstruction strongly supports the epidemiological data. 144
Outcome of hepatocellular carcinoma in human immunodeficiency virus-infected patients. 143
A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients 143
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program 143
Modeling cost-effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real-life cohort 143
Two-Year Treatment with Rosuvastatin Reduces Carotid Intima-Media Thickness in HIV Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy with Asymptomatic Atherosclerosis and Moderate Cardiovascular Risk. 141
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients. 141
Multiplexed therapeutic drug monitoring (TDM) of antiviral drugs by LC–MS/MS 141
Measles outbreak in the city of Bologna, December 2007 to May 2008 140
Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. 140
Incidence of malignancies in HIV-infected patients and prognostic role of current CD4 cell count: evidence from a large Italian cohort study 140
Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. 139
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 139
HCV very late relapse following an atypical viral kinetics in a HIV patient treated for hepatitis C with direct-acting antivirals 138
Hepatitis C virus (HCV) infection in elderly patients: A multicenter Italian cross-sectional study 137
105) ANTIVIRAL TREATMENT OF HEPATITIS C IN ITALIAN CHILDREN 137
Role of Hepatitis C Virus (HCV) Viremia and HCV Genotype in the Immune Recovery from Highly Active Antiretroviral Therapy in a Cohort of Antiretroviral-Naive HIV-Infected Individuals 136
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 135
Improvement in liver steatosis after the switch from a ritonavir-boosted protease inhibitor to raltegravir in HIV-infected patients with non-alcoholic fatty liver disease. 135
Paradoxical immune reconstitution inflammatory syndrome associated with previous Cryptococcus neoformans infection in an HIV-positive patient requiring neurosurgical intervention. 134
Clinical, epidemiological and virological features of acute hepatitis B in Italy. 134
Raltegravir plasma concentrations in treatment-experienced patients receiving salvage regimens based on raltegravir with and without maraviroc coadministration 134
Mortality from HIV and TB coinfections is higher in Eastern Europe than in Western Europe and Argentina. 133
A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of non-responder patients with chronic hepatitic C. 133
Prevalence of antiretroviral drug resistance in untreated persons newly diagnosed with HIV-1 infection 132
Virological failure at one year in triple-class experienced patients switching to raltegravir-based regimens is not predicted by baseline factors 130
Hepatitis B and immigrants: a SIMIT multicenter cross-sectional study. 129
Imaging Features of Microvascular Invasion in Hepatocellular Carcinoma Developed in HCV-Related Cirrhosis after Direct-Acting Antiviral Therapy. 128
Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis 125
Cmv-specific cell-mediated immunity in immunocompetent adults with primary cmv infection: A case series and review of the literature 124
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 123
Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination 122
Hepatitis C Virus (HCV) genotipes in 373 Italian children with HCV infectiona: Changing distribution and correlation with clinical featurees and outcome. 122
Management of chronic hepatitis C in childhood: the impact of therapy in the clinical practice during the first 2 decades 122
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort 121
Patterns and correlations of ALT in a large sample of children with chronic HCV infection 120
Human herpesvirus-8-related Kaposi’s sarcoma after liver transplantation successfully treated with cidofovir and liposomal daunorubicin. 119
Interferon treatment in children with chronic hepatitis C: long-lasting remission in responders, and risk for disease progression in non-responders. 119
Terapia antiretrovirale con inibitori nucleosidici della trascrittasi inversa ed epatotossicità nei pazienti HIV positivi 116
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 115
Epidemiological profile of 806 Italian children with hepatitis C virus infection over a 15-year period. 115
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 115
Una rara complicanza infettiva in corso di trapianto ortotopico di fegato: gestione della peritonite tubercolare 113
Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: An observational cohort study 113
Terapia della infezione da virus C 112
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison 112
Nucleoside analogue transcriptase inhibitors and liver toxicity among patients treated for hiv disease 110
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. 110
SARS-CoV-2 related pneumonia in an adult with cystic fibrosis: natural favourable clinical course or effective therapy? 110
Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals 108
Effect of hepatitisC virus genotype on CD4+T cell count in a cohort of Antiretroviral-naive HIV-1-infeted individuals 107
null 107
Totale 15.372
Salva come PNG Salva come JPEG
Categoria #
all - tutte 55.602
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 55.602
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.279 0 0 0 0 0 156 66 131 186 161 129 450
2021/20222.890 250 126 181 250 229 143 91 251 92 280 574 423
2022/20232.676 273 365 147 387 181 206 71 157 475 91 211 112
2023/2024681 60 125 43 54 49 141 40 55 29 34 20 31
2024/20252.844 119 511 236 232 475 150 182 101 28 160 73 577
2025/20263.449 666 481 642 481 816 363 0 0 0 0 0 0
Totale 20.005